Latest News

If you are wondering whether Itron is fairly priced or offering value right now, you are not alone. The starting point is to understand what the recent share performance is really telling you. The stock last closed at US$100.19, with returns of 0.5% over the past week, 6.3% over the past month, 6.1% year to date, and a 6.8% decline over the past year. The 3 year return sits at 67.3% and the 5 year return at 1.7%. Recent coverage of Itron has focused on its role in providing technology for...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

FINEOS Corporation Holdings plc ( ASX:FCL ) shareholders that were waiting for something to happen have been dealt a...

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

If you are looking at CSX and wondering whether the current share price offers good value, the key question is how that price compares with what the business might reasonably be worth. CSX shares last closed at US$37.87, with returns of 5.8% over the past week, 4.0% over the past month, 4.4% year to date, 17.1% over 1 year, 21.2% over 3 years and 37.4% over 5 years, which puts recent moves in the context of a longer track record. Recent market attention on CSX has been shaped by ongoing...

Fujitsu (TSE:6702) has posted Q3 2026 revenue of ¥884.6 billion and basic EPS of ¥46.39, setting the tone for its latest set of numbers. The company has seen quarterly revenue move from ¥924.8 billion in Q3 2025 to ¥884.6 billion in Q3 2026, while basic EPS shifted from ¥28.95 to ¥46.39 over the same period. This gives investors a clear view of how sales and per share earnings are tracking ahead of the full year. With trailing 12 month net profit margins sitting at 8.8%, slightly higher than...

Stride (LRN) has just posted Q2 2026 results with revenue of US$631.3 million and basic EPS of US$2.31, while trailing twelve month revenue sits at about US$2.5 billion and EPS at US$7.39. Over recent quarters, revenue has moved from US$587.2 million and EPS of US$2.24 in Q2 2025 to US$631.3 million and EPS of US$2.31 in Q2 2026. The trailing net profit margin is 12.7% compared to 12.3% a year earlier, which points to slightly firmer profitability. Taken together, these figures present a...

Lonza Group (SWX:LONN) opened FY 2025 with first half revenue of CHF3.6b and basic EPS of CHF6.08, anchored by net income of CHF426m, setting the tone for how investors will read the rest of the year’s earnings story. The company has seen revenue move from CHF3.1b and EPS of CHF4.61 in the first half of 2024 to CHF3.5b and CHF4.32 in the second half of 2024, before reaching CHF3.6b and CHF6.08 in the first half of 2025. This progression gives investors a clear view of how the top line and EPS...

If you are wondering whether Bausch + Lomb shares offer good value at today's price, it helps to start by looking at what the market has been willing to pay for them recently and how that lines up with the fundamentals we can see. The stock closed at US$16.85 most recently, with a 2.0% decline over the last week, a 1.8% decline over the last month, a 1.6% gain year to date, and a 4.5% decline over the past year. Together, these figures give you a mixed picture of how sentiment has shifted...

If you are wondering whether Biogen's current share price offers good value or if you might be paying too much for its future potential, this article walks through what the numbers are actually saying. Biogen shares closed at US$176.18, with returns of 2.7% over the last 7 days, 0.1% over 30 days, a 0.9% decline year to date, a 22.4% return over 1 year, a 37.9% decline over 3 years and a 33.5% decline over 5 years. This gives a mixed picture for investors weighing recent momentum against...

If you are wondering whether First Horizon's current share price lines up with its underlying worth, you are not alone, and that is exactly what this article will unpack. The stock most recently closed at US$24.42, with returns of 1.2% year to date and 14.5% over the last year. Over the past 5 years it shows a 91.2% return, with a 7 day move of a 0.9% decline and a 30 day return of 2.1%. Recent coverage around First Horizon has focused on its position within the US regional banking sector...

If you are wondering whether Tenet Healthcare's current share price still offers value, this article walks through what the numbers say and how to think about the stock in practical terms. Tenet Healthcare recently closed at US$189.49, with a flat 7 day return, a 5.9% decline over 30 days, a 5.0% decline year to date, and longer term returns of 32.3% over 1 year, 227.5% over 3 years and 280.0% over 5 years. Recent coverage of Tenet Healthcare has focused on its position as a large US...

Concentra Group Holdings Parent (CON) has drawn attention after reporting preliminary Q4 and full year 2025 results that exceeded its earlier guidance, along with fresh 2026 outlook figures and updated investor materials. See our latest analysis for Concentra Group Holdings Parent. The latest guidance and buyback update come after a period where the 30 day share price return of 8.22% and year to date share price return of 11.28% contrast with a 1 year total shareholder return decline of...

If you are wondering whether PTC at around US$153 per share still makes sense for your portfolio, it helps to look closely at what the current price might be implying about the company. The stock has seen a 6.8% decline over the last 7 days, a 12.5% decline over 30 days and is down 9.8% year to date, with a 20.1% decline over the last year, although the 3 year and 5 year returns sit at 16.0% and 10.2% respectively. These moves come as investors continue to reassess software names in general...

Pantoro Gold special call puts Norseman operations in focus Pantoro Gold (ASX:PNR) has scheduled a special call to update investors on operations at its Norseman Gold Project, following the release of the company’s December 2025 Quarterly Activities Report. See our latest analysis for Pantoro Gold. The special Norseman update comes after a choppy few months, with the share price at A$5.09 and a 30 day share price return of 4.09%, alongside a very large 1 year total shareholder return of...

Carpenter Technology (CRS) opened Q2 2026 with total revenue of US$728 million, basic EPS of US$2.10 and net income excluding extra items of US$105.3 million. This put fresh numbers on a year in which trailing twelve month EPS reached US$8.67 on revenue of US$2.9 billion and net income of US$434.7 million. Over the past year, the company has seen quarterly revenue move from US$676.9 million in Q2 2025 to US$728 million in Q2 2026, while basic EPS stepped up from US$1.67 to US$2.10 and...

If you are wondering whether Central Japan Railway shares still offer value after recent attention, it helps to step back and consider what the current price reflects. The stock is trading at ¥4,307 after a 1.1% gain over the last 7 days, with a 50.4% return over 1 year and a 43.6% return over 3 years, alongside a 0.7% decline over 30 days and a 1.9% decline year to date. Recent news coverage has focused on Central Japan Railway as a key transport operator in Japan and its role in broader...

CSG Systems International (NasdaqGS:CSGS) has extended its multi year contract with DISH Network to provide billing and payment platform services. The agreement continues a decades long relationship and is set to run through 2030. The renewal supports DISH Network’s customer experience goals while keeping CSG at the core of its connectivity operations. For investors watching NasdaqGS:CSGS, this long term renewal with a major client comes as the stock trades at $79.65, with a 1 year return...

Perspective Therapeutics recently reported updated interim data from its ongoing Phase 1/2a trial of lead radiopharmaceutical candidate VMT-α-NET, indicating sustained anti-tumor activity, and issued a business update outlining clinical priorities and manufacturing expansion plans. This combination of early clinical signals and investment in production capacity highlights how the company is positioning VMT-α-NET as a core asset in its radiopharmaceutical pipeline. We’ll now examine how the...

Covivio (ENXTPA:COV) has agreed to acquire a hotel under construction in Porto, Portugal, which is pre leased for 20 years to Meininger, adding a fourth asset to their long term partnership. See our latest analysis for Covivio. That Porto hotel deal lands after a period where the 1 year total shareholder return is 12.38%, even as the 30 day share price return shows a 5.12% decline and year to date momentum is softer. If this hotel move has you thinking about where else capital might find long...

Nestlé has recalled multiple batches of its SMA baby formula after regulators confirmed contamination with the food poisoning toxin cereulide traced to a shared third-party ingredient supplier, prompting investigations in France into possible links with two infant deaths. Beyond the immediate product recall, the episode highlights how dependence on external suppliers can expose even large food companies to heightened operational and reputational risk. We will now examine how these food...

Why Neogen (NEOG) is on investors’ radar today Neogen (NEOG) has captured attention after a sharp move in its share price over the past month, with recent performance prompting investors to reassess how the company’s food and animal safety business is currently valued. See our latest analysis for Neogen. That sharp 30 day share price return of 44.82% and 90 day gain of 65.48% contrast with a weaker picture over longer horizons, where the 1 year total shareholder return is a decline of 11.06%...

Alpha HPA has completed a A$225 million follow-on equity offering, issuing up to 313.3 million new ordinary shares at A$0.75 each through an institutional placement and planned share purchase plan to fund construction and commercialisation of Stage 2 of its HPA First Project and expand Stage 1 capacity. A A$75 million cornerstone equity commitment from the National Reconstruction Fund Corporation underscores government backing for Alpha HPA’s aim to build what it describes as the world’s...

NewAmsterdam Pharma (NAMS) is back in focus after management reported positive Phase 3 data for its lead drug obicetrapib in cardiovascular and Alzheimer’s disease indications and highlighted an upcoming European regulatory decision. See our latest analysis for NewAmsterdam Pharma. Despite the recent positive clinical headlines, NewAmsterdam Pharma’s 7 day share price return of 9.68% and 90 day share price return of 17.15% point to cooling momentum, while its 1 year total shareholder return...